Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;103(3):83-89.
doi: 10.1111/iep.12433. Epub 2022 Mar 3.

Investigation of the effect of metoclopramide on proliferation signal molecules in breast tissue

Nurcan Umur  1 , Selda İldan Çalım  2 , Gülce Naz Yazıcı  3 , Seren Gulsen Gurgen  4
Affiliations

Investigation of the effect of metoclopramide on proliferation signal molecules in breast tissue

Nurcan Umur et al. Int J Exp Pathol. 2022 Jun.

Abstract

Metoclopramide (MCP) is a drug that has been widely used in recent years due to its hyperprolactinaemia effect on mothers during breastfeeding. The aim of this study was to investigate the proliferative changes that MCP may cause in the maternal breast tissue. In this study, 18 Wistar albino young-adult breastfeeding mothers with their offspring were divided into three groups: control group, low-dose MCP-applied group and high-dose MCP-applied group. The experiment was carried out during the lactation period and at the end of 21 days. Prolactin, BrdU and Ki-67 breast tissue distributions were evaluated by immunohistochemistry, and tissue levels were evaluated biochemically by the ELISA method. According to ELISA and immunohistochemistry results in breast tissue, there was no significant difference between Ki-67 and BrdU results in all groups. Metoclopramide did not change the expression of proliferation molecules Ki-67 and BrdU in breast tissue. These results suggested that while metoclopramide increases breast proliferation, it does not have the risk of transforming the tissue into a tumour.

Keywords: BrdU; Ki-67; breast tissue; breastfeeding; metoclopramide; prolactin.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Figures

FIGURE 1
FIGURE 1
Breast tissue toluidine blue staining control (A), low‐dose metoclopramide (B) and high‐dose metoclopramide (C). formula image: Mast cells (1) (×100), (2) (×400)
FIGURE 2
FIGURE 2
Breast tissue prolactin immunostaining, control (A), low‐dose metoclopramide (B) and high‐dose metoclopramide (C). formula image: breast epithelial cells showing prolactin positive; *: connective tissue cells, Mayer's haematoxylin counterstain (×400)
FIGURE 3
FIGURE 3
Breast tissue Ki‐67 immunostaining (1) and BrdU immunostaining (2). Control (A), low‐dose metoclopramide (B) and high‐dose metoclopramide (C). formula image: Breast epithelial cells showing Ki‐67‐positive immunoreaction; formula image formula image: breast epithelial cells showing BrdU‐positive immunoreaction, Mayer's haematoxylin counterstain (×400)
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ken K, Nita F. Communicating the benefits of breast feeding. Arch Dis Child. 2007;92:471‐472. - PMC - PubMed
    1. Shamir R. The benefits of breast feeding. Nestle Nutr Inst Workshop Ser. 2016;86:67‐76. - PubMed
    1. Neville MC. Anatomy and physiology of lactation. Pediatr Clin North Am. 2001;48:13‐24. - PubMed
    1. Bazzano AN, Hofer R, Thibeau S, Gillispie V, Jacobs M, Theall KP. A Review of Herbal and Pharmaceutical Galactagogues for Breast‐Feeding. Ochsner J. 2016;16(5):511‐524. - PMC - PubMed
    1. Gabay MP. Galactogogues: medications that induce lactation. J Hum Lact. 2002;18:274‐279. - PubMed

Publication types

LinkOut - more resources